As of February 2022, three Smo antagonists have been approved by the FDA: GDC-0449 (vismodegib) and LDE-225 (sonidegib) for the treatment of BCC, and PF-04449913 (glasdegib) for acute myeloid leukaemia [14]. This evidence concerns the gene SMO and skin basal cell carcinoma.